Financial reports
20-F
2023 FY
Annual report (foreign)
28 Mar 24
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
21 Mar 23
10-K
2022 FY
Annual report
20 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
30 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
10-Q
2021 Q2
Quarterly report
13 Aug 21
Current reports
6-K
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results
7 Mar 24
6-K
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary
3 Jan 24
6-K
Current report (foreign)
9 Nov 23
6-K
Current report (foreign)
14 Aug 23
6-K
Current report (foreign)
8 Aug 23
6-K
Current report (foreign)
3 Jul 23
8-K
Departure of Directors or Certain Officers
16 Jun 23
8-K
Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update
5 Jun 23
8-K
Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update
11 May 23
8-K
Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis
21 Feb 23
Registration and prospectus
F-3/A
Shelf registration (foreign) (amended)
30 Oct 23
F-3
Shelf registration (foreign)
16 Oct 23
RW
Registration withdrawal request
2 Jun 23
S-1/A
IPO registration (amended)
19 May 23
S-1/A
IPO registration (amended)
22 Mar 23
S-1/A
IPO registration (amended)
21 Mar 23
S-1/A
IPO registration (amended)
22 Feb 23
S-1/A
IPO registration (amended)
21 Feb 23
S-1
IPO registration
13 Jan 23
S-8
Registration of securities for employees
15 Aug 22
Proxies
DEFA14A
Additional proxy soliciting materials
31 May 22
DEF 14A
Definitive proxy
28 Apr 22
DEF 14A
Definitive proxy
5 Jan 22
PRE 14A
Preliminary proxy
23 Dec 21
DEF 14A
Definitive proxy
17 Sep 21
PRE 14A
Preliminary proxy
3 Sep 21
DEF 14A
Definitive proxy
14 Jun 21
PRE 14A
Preliminary proxy
1 Jun 21
DEFA14A
Additional proxy soliciting materials
15 Dec 20
DEFA14A
Additional proxy soliciting materials
17 Apr 20
Other
EFFECT
Notice of effectiveness
6 Nov 23
CORRESP
Correspondence with SEC
1 Nov 23
EFFECT
Notice of effectiveness
18 May 21
CORRESP
Correspondence with SEC
12 May 21
UPLOAD
Letter from SEC
5 May 21
EFFECT
Notice of effectiveness
29 Apr 21
CORRESP
Correspondence with SEC
26 Apr 21
UPLOAD
Letter from SEC
23 Apr 21
EFFECT
Notice of effectiveness
11 Feb 21
CORRESP
Correspondence with SEC
10 Feb 21
Ownership
SC 13D/A
OrbiMed Israel BioFund GP Limited Partnership
11 Mar 24
SC 13D/A
OrbiMed Israel BioFund GP Limited Partnership
15 Nov 23
4
Nissim Darvish
5 Jul 23
4
Jill M. Quigley
20 Jun 23
4
Sigal Fatal
16 Jun 23
3
Sigal Fatal
5 Jun 23
4
Alan Charles Moses
23 Mar 23
4
Claude Nicaise
23 Mar 23
4
Neil Harris Cohen
23 Mar 23
4
Nissim Darvish
23 Mar 23